Fuyuan Pharmaceutical announced that it recently received the drug registration certificate for amlodipine benazepril capsules and benazepril hydrochloride (10mg) issued by the State Drug Administration and approved the production of the drug. This drug is used to treat high blood pressure. It was developed by Novartis and was first approved for marketing in the US in March 1995. This product is suitable for patients taking amlodipine or benazepril alone who are unsatisfactory in controlling blood pressure, or for alternative treatment of amlodipine tablets and benazepril tablets at the same time. The company obtained the application acceptance notice on March 21, 2024, and recently obtained approval from the State Drug Administration. According to relevant national policies and regulations, obtaining a “Drug Registration Certificate” this time is considered to have passed the consistency evaluation.

Fuyuan Pharmaceutical announced that it recently received the drug registration certificate for amlodipine benazepril capsules and benazepril hydrochloride (10mg) issued by the State Drug Administration and approved the production of the drug. This drug is used to treat high blood pressure. It was developed by Novartis and was first approved for marketing in the US in March 1995. This product is suitable for patients taking amlodipine or benazepril alone who are unsatisfactory in controlling blood pressure, or for alternative treatment of amlodipine tablets and benazepril tablets at the same time. The company obtained the application acceptance notice on March 21, 2024, and recently obtained approval from the State Drug Administration. According to relevant national policies and regulations, obtaining a “Drug Registration Certificate” this time is considered to have passed the consistency evaluation.